1893 THE SIGNIFICANCE OF COMBINED ANALYSIS OF HUMAN EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1 (HENT1) AND RIBONUCLEOTIDE REDUCTASE M1 (RRM1) IN ADVANCED BLADDER CANCER PATIENTS WITH GEMCITABINE-BASED CHEMOTHERAPY

Abstract

You have accessJournal of UrologyBladder Cancer: Metastatic Disease/Staging1 Apr 20121893 THE SIGNIFICANCE OF COMBINED ANALYSIS OF HUMAN EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1 (HENT1) AND RIBONUCLEOTIDE REDUCTASE M1 (RRM1) IN ADVANCED BLADDER CANCER PATIENTS WITH GEMCITABINE-BASED CHEMOTHERAPY Nagahide Matsumura, Hiroki Kusumoto, Yumiko Sasaki, Satoshi Nishizawa, Kuniyoshi Ura, Kazuro Kikkawa, Yoshiki Kodama, Motohiro Koh, Yasushi Nakamura, Yasuo Kohjimoto, and Isao Hara Nagahide MatsumuraNagahide Matsumura Wakayama City, Japan More articles by this author , Hiroki KusumotoHiroki Kusumoto Wakayama City, Japan More articles by this author , Yumiko SasakiYumiko Sasaki Wakayama City, Japan More articles by this author , Satoshi NishizawaSatoshi Nishizawa Wakayama City, Japan More articles by this author , Kuniyoshi UraKuniyoshi Ura Wakayama City, Japan More articles by this author , Kazuro KikkawaKazuro Kikkawa Wakayama City, Japan More articles by this author , Yoshiki KodamaYoshiki Kodama Wakayama City, Japan More articles by this author , Motohiro KohMotohiro Koh Wakayama City, Japan More articles by this author , Yasushi NakamuraYasushi Nakamura Wakayama City, Japan More articles by this author , Yasuo KohjimotoYasuo Kohjimoto Wakayama City, Japan More articles by this author , and Isao HaraIsao Hara Wakayama City, Japan More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.02.2049AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Human Equilibrative Nucleoside Transporter 1 (hENT1) and Ribonucleotide reductase M1 (RRM1) play important roles in pharmacokinetics of Gemcitabine, and Excision repair cross-complementing 1(ERCC1)is related to drug resistance to CDDP. We evaluated the expression level of these molecules in patients with metastatic bladder cancer treated with Gemcitabine-Cisplatin (GC)-based chemotherapy. METHODS Clinical data were retrieved from the databases from May 2002 to October 2011 in 40 patients (age35-88; male 36 female 4) with advanced bladder cancer treated by GC (Gemcitabine+Cisplatin) regimen (17 pts) and GCT (GC+Paclitaxel) regimen (23 pts). Inclusion criteria for this study were clinically and/or histologically documented advanced and/or metastatic (stage 4) bladder cancer. We performed immunohistochemical staining chemo-naive primary bladder tumor specimens with specific hENT1, RRM1 and ERCC1 antibodies. Pathologists blinded to clinical outcomes evaluated the expression level of these molecules. The clinical and histopathological data were analyzed to evaluate predictive factors. RESULTS With regards to anti tumor response, high hENT1 expression group showed better clinical response comparing with low hENT1 expression group (90% vs 35%, P<0.001). High hENT1 expression group and low RRM1 expression group showed significantly better survival (P<0.001, P=0.01 respectively, Kaplan-Meier curve Fig). Moreover, we classified the cohort patients into 3 subgroups based on the expression level of hENT1 and RRM1. The median survival time in group A was 19.3 months, which was significantly longer than that in Group C (9.9 months). Group B showed the intermediate survival curve between Group A and C (P<0.001, Kaplan-Meier curve, Fig). CONCLUSIONS The expression of hENT1 and RRM1 was associated with prolonged survival in patients with metastatic bladder cancer treated with GC-based chemotherapy. The combined analysis of hENT1 and RRM1 expression can be a promising biomarker which can predict the clinical response and the prognosis of patients with advanced bladder cancer treated by gemcitabine-based chemotherapy. © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 187Issue 4SApril 2012Page: e763-e764 Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.MetricsAuthor Information Nagahide Matsumura Wakayama City, Japan More articles by this author Hiroki Kusumoto Wakayama City, Japan More articles by this author Yumiko Sasaki Wakayama City, Japan More articles by this author Satoshi Nishizawa Wakayama City, Japan More articles by this author Kuniyoshi Ura Wakayama City, Japan More articles by this author Kazuro Kikkawa Wakayama City, Japan More articles by this author Yoshiki Kodama Wakayama City, Japan More articles by this author Motohiro Koh Wakayama City, Japan More articles by this author Yasushi Nakamura Wakayama City, Japan More articles by this author Yasuo Kohjimoto Wakayama City, Japan More articles by this author Isao Hara Wakayama City, Japan More articles by this author Expand All Advertisement Advertisement PDF DownloadLoading ...